PDL Biopharma (PDLI) 8-K PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results

Exhibit 99.3

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin	Q1	Q2	Q3	Q4	Total
2011	1,597,461	1,582,705	1,581,095	1,469,994	6,231,255
2010	1,506,788	1,596,892	1,594,707	1,646,218	6,344,605
2009	1,345,487	1,295,536	1,439,730	1,514,053	5,594,806
2008	980,715	1,084,930	1,180,427	1,239,382	4,485,454
2007	678,068	746,587	797,013	875,084	3,096,752
2006	439,318	516,052	570,551	592,897	2,118,817

Herceptin	Q1	Q2	Q3	Q4	Total
2011	1,391,568	1,559,975	1,642,898	1,432,771	6,027,211
2010	1,270,846	1,349,512	1,300,934	1,409,310	5,330,602
2009	1,210,268	1,133,993	1,226,435	1,278,626	4,849,323
2008	1,105,426	1,195,215	1,211,982	1,186,806	4,699,428
2007	891,761	949,556	979,602	1,015,033	3,835,952
2006	529,585	659,719	761,099	803,576	2,753,979

Lucentis	Q1	Q2	Q3	Q4	Total
2011	887,757	943,418	1,052,809	1,075,015	3,958,999
2010	721,967	698,890	745,376	804,684	2,970,917
2009	462,103	469,736	555,296	615,212	2,102,347
2008	363,615	393,682	460,167	454,922	1,672,386
2007	224,820	219,579	299,995	322,300	1,066,695
2006	-	-	10,689	157,742	168,431

Xolair	Q1	Q2	Q3	Q4	Total
2011	267,754	277,642	310,874	314,911	1,171,182
2010	228,859	225,878	251,055	263,389	969,179
2009	184,669	181,086	211,006	219,693	796,454
2008	137,875	169,521	177,179	183,753	668,329
2007	129,172	130,700	144,250	147,754	551,876
2006	95,241	99,354	112,608	118,002	425,204

Tysabri	Q1	Q2	Q3	Q4	Total
2011	329,696	356,876	388,758	381,618	1,456,948
2010	293,047	287,925	293,664	316,657	1,191,292
2009	221,854	229,993	257,240	285,481	994,569
2008	129,430	163,076	200,783	233,070	726,359
2007	30,468	48,715	71,972	94,521	245,675
2006	-	-	-	7,890	7,890

Actemra	Q1	Q2	Q3	Q4	Total
2011	30,433	35,370	46,709	48,671	161,183
2010	52,908	5,405	10,493	22,919	91,725
2009	19,504	17,920	30,313	39,888	107,625
2008	1,452	1,377	5,981	12,305	21,115
2007	-	-	-	1,137	1,137
2006	-	-	-	-	-

*  As reported to PDL by its licensees

Totals may not sum due to rounding

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1	Q2	Q3	Q4	Total
2011	22,283	41,967	23,870	22,886	111,006
2010	16,870	44,765	29,989	24,922	116,547
2009	13,605	35,161	21,060	15,141	84,966
2008	9,957	30,480	19,574	12,394	72,405
2007	8,990	21,842	17,478	9,549	57,859
2006	10,438	15,572	15,405	12,536	53,952

Herceptin	Q1	Q2	Q3	Q4	Total
2011	25,089	42,209	31,933	21,812	121,042
2010	23,402	38,555	27,952	25,441	115,350
2009	16,003	32,331	26,830	18,615	93,779
2008	14,092	34,383	28,122	20,282	96,880
2007	19,035	28,188	22,582	14,802	84,608
2006	15,142	19,716	21,557	20,354	76,769

Lucentis	Q1	Q2	Q3	Q4	Total
2011	8,878	24,313	12,157	10,750	56,099
2010	7,220	19,091	10,841	8,047	45,198
2009	4,621	12,863	8,123	6,152	31,759
2008	3,636	11,060	7,631	4,549	26,876
2007	2,931	6,543	6,579	3,517	19,570
2006	-	-	289	3,335	3,624

Xolair	Q1	Q2	Q3	Q4	Total
2011	4,590	7,621	5,916	5,823	23,949
2010	3,723	6,386	4,980	4,652	19,741
2009	2,665	5,082	4,085	3,722	15,553
2008	1,488	4,866	3,569	2,927	12,850
2007	1,684	3,942	3,332	2,184	11,142
2006	2,263	2,969	3,041	2,495	10,768

Tysabri	Q1	Q2	Q3	Q4	Total
2011	9,891	10,796	11,588	11,450	43,725
2010	8,791	8,788	8,735	9,440	35,754
2009	6,656	7,050	7,642	8,564	29,912
2008	3,883	5,042	5,949	6,992	21,866
2007	839	1,611	2,084	2,836	7,370
2006	-	-	-	237	237

Actemra	Q1	Q2	Q3	Q4	Total
2011	913	1,136	1,401	1,460	4,910
2010	1,587	237	315	688	2,827
2009	585	537	909	1,197	3,228
2008	44	-	146	369	559
2007	32	-	-	17	49
2006	-	-	-	-	-

* As reported to PDL by its licensees

Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2010 - Q3	2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4
US Made & Sold	820,453	800,139	708,539	719,967	688,966	684,878
US Made & ex-US Sold	338,929	415,576	580,981	548,710	587,975	375,830
ex-US Made & Sold	435,325	430,503	307,941	314,028	304,155	409,286
Total	1,594,707	1,646,218	1,597,461	1,582,705	1,581,095	1,469,994
US Made & Sold	51%	49%	44%	45%	44%	47%
US Made & ex-US Sold	21%	25%	36%	35%	37%	26%
ex-US Made & Sold	27%	26%	19%	20%	19%	28%

Herceptin Sales	2010 - Q3	2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4
US Made & Sold	410,563	416,611	409,854	442,903	445,395	453,168
US Made & ex-US Sold	306,085	425,303	423,053	642,670	495,086	612,908
ex-US Made & Sold	584,286	567,396	558,661	474,402	702,416	366,695
Total	1,300,934	1,409,310	1,391,568	1,559,975	1,642,898	1,432,771
US Made & Sold	32%	30%	29%	28%	27%	32%
US Made & ex-US Sold	24%	30%	30%	41%	30%	43%
ex-US Made & Sold	45%	40%	40%	30%	43%	26%

Lucentis Sales	2010 - Q3	2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4
US Made & Sold	326,840	360,911	378,451	409,674	422,335	428,884
US Made & ex-US Sold	418,536	443,773	509,307	533,745	630,474	646,131
ex-US Made & Sold	-	-	-	-	-	-
Total	745,376	804,684	887,757	943,418	1,052,809	1,075,015
US Made & Sold	44%	45%	43%	43%	40%	40%
US Made & ex-US Sold	56%	55%	57%	57%	60%	60%
ex-US Made & Sold	0%	0%	0%	0%	0%	0%

Xolair Sales	2010 - Q3	2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4
US Made & Sold	165,109	170,001	164,621	167,608	184,837	188,728
US Made & ex-US Sold	-	-	-	-	-	-
ex-US Made & Sold	85,945	93,388	103,133	110,034	126,037	126,184
Total	251,055	263,389	267,754	277,642	310,874	314,911
US Made & Sold	66%	65%	61%	60%	59%	60%
US Made & ex-US Sold	0%	0%	0%	0%	0%	0%
ex-US Made & Sold	34%	35%	39%	40%	41%	40%

Total Sales	2010 - Q3	2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4
US Made & Sold	1,722,965	1,747,662	1,661,465	1,740,152	1,741,534	1,755,657
US Made & ex-US Sold	1,063,551	1,284,652	1,513,340	1,725,125	1,713,535	1,634,869
ex-US Made & Sold	1,105,556	1,091,287	969,735	898,464	1,132,608	902,165
Total	3,892,072	4,123,601	4,144,540	4,363,741	4,587,677	4,292,691
US Made & Sold	44%	42%	40%	40%	38%	41%
US Made & ex-US Sold	27%	31%	37%	40%	37%	38%
ex-US Made & Sold	28%	26%	23%	21%	25%	21%

*  As reported to PDL by its licensees

Totals may not sum due to rounding